Efficacy of Vedolizumab for Refractory Pouchitis of the Ileo-anal Pouch: Results From a Multicenter US Cohort.
暂无分享,去创建一个
H. Herfarth | P. Beniwal-Patel | E. Barnes | A. Gutierrez | P. Deepak | M. Ciorba | L. Raffals | Martin H. Gregory | Devin N. Patel | G. Christophi | K. Weaver | P. Hoversten | S. B. Hicks | Sowmya Palam | Gaurav Syal | Alexandra M. Gutierrez | Kimberly N Weaver | Laura E. H. Raffals
[1] S. Danese,et al. Inflammatory bowel disease position statement of the Italian Society of Colorectal Surgery (SICCR): ulcerative colitis , 2020, Techniques in Coloproctology.
[2] M. Dubinsky,et al. Endoscopic activity in asymptomatic patients with an ileal pouch is associated with an increased risk of pouchitis , 2019, Alimentary pharmacology & therapeutics.
[3] O. Cakir. Effectiveness of vedolizumab treatment in two different anti-tumor necrosis factor alpha refractory pouchitis: A case report , 2019, World journal of clinical cases.
[4] S. Vermeire,et al. Outcome of biological therapies in chronic antibiotic-refractory pouchitis: A retrospective single-centre experience , 2019, United European gastroenterology journal.
[5] H. Herfarth,et al. Ustekinumab Is Effective for the Treatment of Crohn's Disease of the Pouch in a Multicenter Cohort. , 2018, Inflammatory bowel diseases.
[6] M. Silverberg,et al. Reliability among central readers in the evaluation of endoscopic disease activity in pouchitis. , 2018, Gastrointestinal endoscopy.
[7] B. Shen,et al. Vedolizumab in the treatment of Crohn’s disease of the pouch , 2018, Gastroenterology report.
[8] N. Teich,et al. Vedolizumab in the treatment of chronic, antibiotic‐dependent or refractory pouchitis , 2018, Alimentary pharmacology & therapeutics.
[9] F. Caprioli,et al. Successful Treatment With Vedolizumab in a Patient With Chronic Refractory Pouchitis and Primary Sclerosing Cholangitis. , 2017, Journal of Crohn's & colitis.
[10] V. Tahan,et al. Successful treatment of chronic refractory pouchitis with vedolizumab , 2017, International Journal of Colorectal Disease.
[11] Christopher F. Martin,et al. Pouch-Related Symptoms and Quality of Life in Patients with Ileal Pouch–Anal Anastomosis , 2017, Inflammatory bowel diseases.
[12] S. Travis,et al. Systematic review: the safety of vedolizumab for the treatment of inflammatory bowel disease , 2017, Alimentary pharmacology & therapeutics.
[13] S. Schreiber,et al. Combination therapy with vedolizumab and etanercept in a patient with pouchitis and spondylarthritis , 2017, BMJ open gastroenterology.
[14] M. Goetz,et al. Successful treatment of pouchitis with Vedolizumab, but not fecal microbiota transfer (FMT), after proctocolectomy in ulcerative colitis , 2017, International Journal of Colorectal Disease.
[15] B. Shen,et al. Efficacy of Vedolizumab in Patients with Antibiotic and Anti-tumor Necrosis Alpha Refractory Pouchitis. , 2017, Inflammatory bowel diseases.
[16] John T. Chang,et al. The Real-World Effectiveness and Safety of Vedolizumab for Moderate–Severe Crohn’s Disease: Results From the US VICTORY Consortium , 2016, American Journal of Gastroenterology.
[17] A. Lightner,et al. Crohn's Disease of the Ileoanal Pouch , 2016, Inflammatory bowel diseases.
[18] Chien-Huan Chen,et al. Vedolizumab Effectiveness and Safety Over the First Year of Use in an IBD Clinical Practice. , 2016, Journal of Crohn's & colitis.
[19] A. Ananthakrishnan,et al. Efficacy of Vedolizumab as Induction Therapy in Refractory IBD Patients: A Multicenter Cohort , 2015, Inflammatory bowel diseases.
[20] F. Remzi,et al. Do Clinical Characteristics of de Novo Pouch Crohn’s Disease After Restorative Proctocolectomy Affect Ileal Pouch Retention? , 2014, Diseases of the colon and rectum.
[21] B. Shen. Pouchitis: what every gastroenterologist needs to know. , 2013, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[22] Kristin Stephens,et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. , 2013, The New England journal of medicine.
[23] Liam A. Haveran,et al. Infliximab and/or Azathioprine in the Treatment of Crohn's Disease-Like Complications After IPAA , 2011, Diseases of the colon and rectum.
[24] P. Harris,et al. Research electronic data capture (REDCap) - A metadata-driven methodology and workflow process for providing translational research informatics support , 2009, J. Biomed. Informatics.
[25] J. Goldblum,et al. Administration of adalimumab in the treatment of Crohn’s disease of the ileal pouch , 2009, Alimentary pharmacology & therapeutics.
[26] P. Rutgeerts,et al. Outcome after proctocolectomy with ileal pouch‐anal anastomosis for ulcerative colitis , 2008, Inflammatory bowel diseases.
[27] V. Fazio,et al. Clinical Features and Quality of Life in Patients with Different Phenotypes of Crohn’s Disease of the Ileal Pouch , 2007, Diseases of the colon and rectum.
[28] W. Sandborn,et al. Management of Crohn's disease of the ileoanal pouch with infliximab , 2003, American Journal of Gastroenterology.
[29] R. Caprilli,et al. Infliximab in refractory pouchitis complicated by fistulae following ileo‐anal pouch for ulcerative colitis , 2003, Alimentary pharmacology & therapeutics.
[30] T. Madiba,et al. Pouchitis following restorative proctocolectomy for ulcerative colitis: incidence and therapeutic outcome. , 2001, Journal of the Royal College of Surgeons of Edinburgh.
[31] Chang-Sik Yu,et al. Ileal pouch-anal anastomosis in patients with indeterminate colitis , 2000, Diseases of the colon and rectum.
[32] K. Batts,et al. Pouchitis after ileal pouch-anal anastomosis: a Pouchitis Disease Activity Index. , 1994, Mayo Clinic proceedings.